Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

PURPOSE: The purpose of this study was to estimate the overall survival (OS) in real-world clinical practice in patients with metastatic breast cancer (MBC) and visceral metastases (liver or lung) treated in the third-line setting with eribulin, gemcitabine or capecitabine overall and in the major c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazmi, Shayma, Chatterjee, Debanjana, Raju, Dheeraj, Hauser, Rob, Kaufman, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599186/
https://www.ncbi.nlm.nih.gov/pubmed/32808239
http://dx.doi.org/10.1007/s10549-020-05867-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599186/
https://www.ncbi.nlm.nih.gov/pubmed/32808239
http://dx.doi.org/10.1007/s10549-020-05867-0

Ejemplares similares